UK markets closed
NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.72 +0.70 (+0.90%) GOLD FUTURES
2,391.90 +32.00 (+1.36%) DOW
39,827.62 +269.51 (+0.68%) Bitcoin GBP
51,691.05 +3,311.86 (+6.85%)
Dyne Therapeutics, Inc. (DYN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 02:42PM EDT. Market open.
| Previous close | 28.16 |
| Open | 28.69 |
| Bid | 29.31 x 100 |
| Ask | 29.53 x 100 |
| Day's range | 28.38 - 29.88 |
| 52-week range | 6.40 - 30.27 |
| Volume | |
| Avg. volume | 1,237,481 |
| Market cap | 2.569B |
| Beta (5Y monthly) | 1.00 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.98 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 39.22 |
Simply Wall St.We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- GuruFocus.com
Dyne Therapeutics Inc (DYN) Q1 2024 Earnings: Aligns with Analyst Projections
Overview of Financial Performance and Future Prospects
GlobeNewswireDyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter of 2024 and recent business highlights. “I am excited about
© 2024 Yahoo. All rights reserved.